ClinicalTrials.gg
CompletedNCT04522843Updated Dec 18, 2024

Analysis of Intestinal Defensin Expression in Acute GVHD

An observational study in GVHD,Acute, Ulcerative Colitis and Morbus Crohn, sponsored by University of Freiburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by University of Freiburg · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
80
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 243 studies in Colitis, Ulcerative with a site in Germany — 29 open to participants now, 62 under way, 26 of them phase 3. Colitis, Ulcerative · Germany.

Enrollment
33rd of 41
80 · median 378
Started
2018
with 17 others
Observational
41 of 243
8 open now
Registered
159th of 243
by date

Among the 243 studies in Colitis, Ulcerative with a site in Germany, this one is the 33rd largest by enrollment of the 41 observational ones that give a count, is one of 18 that started in 2018, is one of 41 observational ones, and was the 159th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 243 studies in Colitis, Ulcerative with a site in Germany are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Colitis, Ulcerative with a site in Germany, or all of them as a file.
02

Study summary

This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.

Read the detailed description

Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD is characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal dysbiosis, which contribute to disease pathogenesis. Defensins are endogenous epithelial cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape the intestinal microbiota composition and contribute to host immunoregulation. Deregulated expression of defensins has been reported in patients with colitis, including Chron's Disease and ulcerative colitis.

In this study, the investigators aim to analyze the expression of defensins in the intestine of patients with acute GVHD to study whether it is deregulated. The results will be valuable to study the role of defensins during acute GVHD pathogenesis or as potential biomarkers for disease activity.

03

Conditions studied

  • GVHD,Acute
  • Ulcerative Colitis
  • Morbus Crohn
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who underwent diagnostic endoscopy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥ 18 years
  • diagnostic endoscopy was performed
  • diagnosis results available
  • written
  • ability to understand the nature of the study and the study related procedures and to comply with them

Exclusion criteria

Exclusion Criteria:

  • age \< 18 years
  • gastrointestinal cancer
  • lack of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
80 participants (actual)
Patient registry
No

Groups and cohorts

  • Uninflamed intestine

    Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation

  • Colitis

    Patients with active colitis

  • Acute GVHD

    Patients with acute gastrointestinal (GI) GVHD

06

What researchers measure

Primary outcomes

  1. Defensin Expression (mRNA)

    Analysis of alpha-defensin and beta-defensin mRNA expression by realtime PCR (qRT-PCR)

    Time frame: 3 years

  2. Defensin Expression (peptide)

    Analysis of alpha-defensin and beta-defensin levels by immunohistochemistry

    Time frame: 3 years

07

Study locations

1 site
  • Medical Center University of Freiburg
    Freiburg, Baden-Württemberg 79106, Germany
08

References and documents

Publications

  • Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschlager C, Feller AC, Stange EF. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002 Jul;14(7):745-52. doi: 10.1097/00042737-200207000-00006. PubMed 12169983 ↗
  • Kohler N, Zeiser R. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD. Front Immunol. 2019 Jan 17;9:3179. doi: 10.3389/fimmu.2018.03179. eCollection 2018. PubMed 30705680 ↗
  • Ruckert T, Andrieux G, Boerries M, Hanke-Muller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Kohler N. Human beta-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PubMed 36542690 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Oct 2024, 73 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 21, 2020
StartActual
Sep 1, 2018
Primary completionActual
Oct 30, 2024
CompletionActual
Oct 30, 2024
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04522843
Lead sponsor
University of Freiburg
Responsible party
Robert Zeiser (Director of the Division of Tumor Immunology, University of Freiburg) — Principal investigator
First posted
Aug 21, 2020
Start date
Sep 1, 2018
Primary completion
Oct 30, 2024
Completion
Oct 30, 2024
Last update
Dec 18, 2024

Study contacts

Robert Zeiser, Prof. Dr.
principal investigator · Medical Center University of Freiburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion